Skip to main content

ADC Therapeutics SA

ADCT
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001771910

No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding ADC Therapeutics SA changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of ADCT: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders6660−6
Shares36.6M38.8M+2.21M (+6.0%)
Value$176.5M$149.1M−$27.4M (−15.5%)

New holders (16)

Institutions that held ADC Therapeutics SA at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to ADCT in Q4 2022
InstitutionSharesValue% of portfolio
Point72 Asset Management, L.P.704,500$2.71M0.01%
AlphaCentric Advisors LLC297,500$1.14M1.13%
Nantahala Capital Management, LLC243,290$934.2K0.08%
Occudo Quantitative Strategies LP61,858$237.5K0.03%
Two Sigma Investments, LP54,896$210.8K0.00%
Schonfeld Strategic Advisors LLC31,300$120.2K0.00%
Russell Investments Group, Ltd.17,800$68.4K0.00%
IHT Wealth Management, LLC15,110$58.0K0.00%
Values First Advisors, Inc.10,400$39.9K0.03%
UBS Group AG2,916$11.2K0.00%
Acadian Asset Management LLC2,695$10.0K0.00%
Belpointe Asset Management LLC1,724$6.62K0.00%
Aquatic Capital Management LLC700$3.00K0.00%
Money Concepts Capital Corp74$2840.00%
GWM Advisors LLC36$1380.00%
Ronald Blue Trust, Inc.31$00.00%

Sold out (22)

Institutions that held ADC Therapeutics SA at the end of Q3 2022 and filed for Q4 2022 without it.